Pliant Therapeutics, Inc.
PLRX
Last
$1.00
Day
+2.0%
1y
-35.1%
5y
-94.2%
52w
-48.7%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0525d
EMA 21
1.07
EMA 50
1.09
EMA 200
1.38
20d high
-15.3%
5y high
-97.3%
5y range
0th
Positions held
Your positionsPLRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$1.08
Stop
$0.94
Stop distance
6.0%
Target vs last
+8.0%
Fundamentals
| Market cap | $61.92M | Enterprise value | -$67.44M | Trailing P/E | — | Forward P/E | -0.78 |
| PEG | — | Price / book | 0.42 | Beta | 1.28 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -50.3% | ROA | -23.3% | Debt / equity | 0.20 |
| Current ratio | 9.90 | Free cash flow | -$42.51M | Analyst recommendation | none | Mean target | $2.00 |
| 52w high | $1.95 | 52w low | $0.97 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$22.4M | -$20.0M | -$23.6M | -$26.3M | -$43.3M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.9M | -$21.8M | -$23.6M | -$28.3M | -$45.6M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $1.6M | $9.7M | — |
| Op margin | — | — | -11654.7% | -1313.4% | — |
| Net income | -$149M | -$210M | -$161M | -$123M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$156M | -$228M | -$184M | -$127M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Pliant Therapeutics Appoints David Raben as Chief Medical Officer
2026-09-30 · Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
2026-08-11 · Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
2026-07-13 · Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
Price (daily)
Full chart · RSI · MACD · patternsPLRX · daily-12.3% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin